Haisco Pharmaceutical Group Co. Ltd. has disclosed new muscarinic M4 receptor agonists described as potentially useful for the treatment of substance abuse and dependence, Alzheimer’s disease, pain, schizophrenia and sleep disorders.
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official disclosure of some billion-dollar collaborations, leading with Abbvie Inc.’s exclusive licensing deal with Remegen Co. Ltd. for PD-1/VEGF-targeted bispecific antibody RC-148.
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official disclosure of some billion-dollar collaborations, leading with Abbvie Inc.’s exclusive licensing deal with Remegen Co. Ltd. for PD-1/VEGF-targeted bispecific antibody RC-148.
Haisco Pharmaceutical Group Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to antitumor drugs through a linker reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has synthesized G protein-coupled receptor GPR52 agonists reported to be useful for the treatment of psychiatric disorders.
Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as TNF-α/tumor necrosis factor receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative colitis and rheumatoid arthritis.
Haisco Pharmaceutical Group Co. Ltd. has identified interleukin-17A (IL-17A) production inhibitors with reduced toxic and side effects reported to be useful for the treatment of arthritis, multiple sclerosis and psoriasis.
Haisco Pharmaceutical Group Co. Ltd. has divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of inflammatory, renal, psychiatric, cardiovascular, eye, respiratory and metabolic disorders, as well as cancer.
Haisco Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR (HER1; erbB1)-targeting moiety through a linker.
Haisco Pharmaceutical Group Co. Ltd. has identified compounds acting as TNF-α/TNF receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis and rheumatoid arthritis.
